PTC299
CAS No. 1256565-36-2
PTC299( PTC-299 | PTC 299 )
Catalog No. M11050 CAS No. 1256565-36-2
PTC299 (PTC-299) is a novel potent inhibitor of dihydroorotate dehydrogenase (DHODH), inhibits hypoxia-induced VEGFA protein production in HeLa cells with IC50 of 1.64 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 250 | In Stock |
|
| 5MG | 242 | In Stock |
|
| 10MG | 370 | In Stock |
|
| 25MG | 622 | In Stock |
|
| 50MG | 867 | In Stock |
|
| 100MG | 1181 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePTC299
-
NoteResearch use only, not for human use.
-
Brief DescriptionPTC299 (PTC-299) is a novel potent inhibitor of dihydroorotate dehydrogenase (DHODH), inhibits hypoxia-induced VEGFA protein production in HeLa cells with IC50 of 1.64 nM.
-
DescriptionPTC299 (PTC-299) is a novel potent inhibitor of dihydroorotate dehydrogenase (DHODH), inhibits hypoxia-induced VEGFA protein production in HeLa cells with IC50 of 1.64 nM; inhibited DHODH activity more potently than teriflunomide and with potency similar to that of brequinar, demonstrates broad and potent activity against hematological cancer cells in preclinical models, inhibits AML patient-derived cells with IC50 of 2-60 nM; demonstrates advantages over previously reported DHODH inhibitors, including greater potency, good oral bioavailability and lack of off-target kinase inhibition and myelosuppression.Breast Cancer Phase 1 Clinical.
-
In VitroPTC299 inhibits hypoxia-induced VEGFA protein production in HeLa cells with an EC50 of 1.64 ± 0.83 nM.PTC299 is the most potent inhibitor with an IC50 of about 1 nM, over 10 to 1000-fold more potent than Brequinar, Vidofludimus or A 77-1726 in leukemia cells.
-
In Vivo——
-
SynonymsPTC-299 | PTC 299
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1256565-36-2
-
Formula Weight467.346
-
Molecular FormulaC25H20Cl2N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (106.99 mM)
-
SMILESCOC1=CC=C(C=C1)C2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl
-
Chemical Name4-chlorophenyl (S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Relacorilant
Relacorilant is a selective and orally bioavailable antagonist of glucocorticoid receptor.
-
Methyl retinoate
Methyl retinoate (Retinoic acid, methyl ester) induces aseptic inflammation at the site of administration in in vivo experiments, which causes an increase in the number of leukocytes in the blood and a decrease in the levels of red blood cells and Hb.Methyl retinoate promotes spontaneous leukemia.Methyl retinoate can be Used in the treatment of gastric hypertrophy and ulcers due to vitamin A deficiency.
-
Pomalidomide-PEG4-C-...
Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
Cart
sales@molnova.com